← Evidence library

BIB_162

Long GV et al. Adjuvant pembrolizumab vs placebo in resected stage IIB/IIC melanoma (KEYNOTE-716): randomised, double-blind, phase 3 trial. Lancet 2022;399(10336):1718–1729. PMID 35367448. n=976; RFS HR 0.65 at first interim; sustained at 39mo. FDA 2021/EMA 2022/NICE TA 2023/SMC Scotland 2023. [Tasks: 17, 18] Tier: 1 Grade: A Retrieved: 2026-05-07

Evidence grade

A

Tier

1

Cited by tasks

17, 18

Identifiers

PMID:35367448

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_162/findings.md (research corpus). This page is a short context summary — not individualised medical advice.